Navigation Links
Dr. Bob Harman, CEO of VetStem Biopharma, Speaks on Stem Cells at Local Rotary Club
Date:10/10/2017

Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent an afternoon speaking at his local San Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 in San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont Hospital and Darryl D’Lima MD, PhD, Director of Orthopedic Research, Shiley Center for Orthopedic Research and Education.

Dr. Harman’s talk centered on the use of stem cells in veterinary medicine. At VetStem Biopharma, the primary indications for stem cells are osteoarthritis as well as bone and soft tissue injuries in the dog, horse, and cat. While VetStem has been providing this service to veterinarians across the United States and Canada since 2004, human doctors have not adopted this treatment modality as quickly.

Although VetStem specializes in veterinary medicine, ongoing development of the technology may have larger implications for stem cell use in human medicine. One might ask, “If stem cells can help my dog’s hip osteoarthritis, could it help mine?” The answer is likely yes. Dr. Harman presents regularly at human stem cell conferences, sharing VetStem data and findings. With data compiled from over 13,000 veterinary patients, VetStem has a lot to share. Dr. Harman has also authored and co-authored several papers and book chapters on both human and veterinary stem cells.

In an effort to make stem cell therapy less costly and more accessible, Dr. Harman and his team are working toward FDA approval of an “off-the-shelf,” or allogeneic (donor derived), stem cell product. VetStem completed a landmark double-blinded, multi-site, placebo-controlled field efficacy study in 2016 which enrolled approximately 90 dogs with osteoarthritis. The dogs, who received a single intra-articular injection of stem cells, demonstrated a statistically significant improvement in treatment versus placebo (p<0.05). The primary endpoint was treatment success based on the Client-Specific Outcome Measurement (CSOM) on day 60 as compared to day 0. Additionally, the veterinary assessment of pain showed a statistically significant improvement in the stem cell treated dogs compared to the controls. To further development, VetStem is currently conducting a pivotal FDA clinical study of osteoarthritis in the dog with an expected completion date of late 2017. With these results, VetStem hopes to receive FDA approval of the canine allogeneic stem cell product in 2018-19.

About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 13,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14782362.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. VetStem Biopharma CEO and Founder, Dr. Bob Harman, Interviewed in New Book "Stem Cell Therapy: A Rising Tide"
2. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, will present a clinical abstract on Allogeneic Adipose Stem Cell Bio-Distribution at the Veterinary Orthopedic
3. New Book Out with Two Chapters on Veterinary Regenerative Medicine Written by Dr. Bob Harman, CEO for VetStem Biopharma, Now Available through Amazon
4. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium
5. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Present at Third Annual Clinical and Surgical Translation of Stem Cells
6. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
7. Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet
8. Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc.
9. Vet-Stem, Inc. Founder and CEO, Dr. Robert Harman, to Speak at North American Veterinary Regenerative Medicine Association Conference
10. Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Invited to Speak at the Adult Stem Cell Therapy and Regenerative Medicine Conference
11. Vet-Stem, Inc. Founder, Robert Harman, DVM, Invited as Inspirational Speaker for the 6th Annual After the Finish Line Charity Dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... DuPont Pioneer and recently formed CasZyme, ... into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal ... editing across all applications. , Under the terms of the agreement, Pioneer will ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):